Intestinal decontamination with non-absorbable antibiotics restored eubiosis, decreased intestinal inflammation and permeability, and reduced

alcoholic liver disease in mice suggesting that alcohol-associated dysbi-osis induces intestinal inflammation and leakiness. To further define the role of TNFα in mediating intestinal barrier dysfunction following alcohol administration, we focused on the main receptor for TNFα, TNF-receptor 1 (TNFR-1). TNFR-1 mutant mice (TNFR-1flxneo/flxneo) were protected from intestinal barrier dysfunction as evidenced by higher levels of fecal albumin and decreased hepatic contents of bacterial products. TNFR-1 mutant mice had less liver disease as shown by lower plasma ALT levels and hepatic triglycerides. To investigate Everolimus whether TNFR-1 on intestinal epithelial cells mediates intestinal barrier dysfunction and liver disease, a functional TNFR-1 was selectively expressed click here on intestinal epithelial cells

by crossing TNFR-1flxneo/flxneo mice with Villin-Cre transgenic mice. Reactivation of TNFR-1 on enterocytes resulted in increased intestinal permeability and liver disease that is similar to wild type mice after alcohol feeding, suggesting that enteric TNFR-1 promotes intestinal barrier dysfunction and mediates alcoholic liver disease. Myosin light chain kinase (MLCK) is a downstream target of TNFα and was phosphorylated in intestinal epithelial cells following alcohol administration. Intestinal barrier loss was reduced in MCE公司 MLCK−/− mice after ch ronic alcohol feeding. While hepatic steatosis was lower in MLCK−/− mice as compared with wild type mice, liver injury was not reduced suggesting that intestinal MLCK partially

contributes to intestinal leakiness and liver disease. Conclusion: Dysbiosis-induced intestinal inflammation and TNFR-1 signaling in intestinal epithelial cells are mediating a disruption of the intestinal barrier following chronic alcohol feeding. Therefore, intestinal TNFR-1 is a crucial mediator of alcoholic liver disease. Disclosures: Samuel B. Ho – Consulting: Genentech; Grant/Research Support: Roche The following people have nothing to disclose: Peng Chen, Peter Starkel, Jerrold R. Turner, Bernd Schnabl Alcoholic liver disease is a major health issue worldwide, but effective therapies are currently unavailable. The present study tested the efficacy of Alda-1, an activator of aldehyde dehydrogenase 2, in treating alcoholic liver disease. Male C57BL/6J mice were exposed to alcohol for up to 8 weeks for a time-course study on aldehyde metabolism. The effects of Alda-1 on aldehyde dehydrogenase 2 and aldehyde clearance were determined after acute alcohol intoxication. Mice were exposed to alcohol for 8 weeks with or without Alda-1 administration for the last 10 days to test the therapeutic potential of Alda-1.